AU Patent

AU2013239816B2 — Lactam kinase inhibitors

Assigned to G1 Therapeutics Inc · Expires 2017-08-24 · 9y expired

What this patent protects

Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.

USPTO Abstract

Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: AU2013239816B2
Jurisdiction: AU
Classification: —
Expires: 2017-08-24
Drug substance claim: No
Drug product claim: No
Assignee: G1 Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.